Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

by Plavina, Tatiana, Subramanyam, Meena, Bloomgren, Gary, Richman, Sandra, Pace, Amy, Lee, Sophia, Schlain, Brian, Campagnolo, Denise, Belachew, Shibeshih, Ticho, Barry
Published 2014

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

by Fox, Robert J., Cree, Bruce A.C., De Sèze, Jerome, Gold, Ralf, Hartung, Hans-Peter, Jeffery, Douglas, Kappos, Ludwig, Kaufman, Michael, Montalbán, Xavier, Weinstock-Guttman, Bianca, Anderson, Britt, Natarajan, Amy, Ticho, Barry, Duda, Petra
Published 2014